Developmental Toxicity of Mycotoxin *Fumonisin* B$_1$ in Animal Embryogenesis: An Overview

Chompunut Lumsangkul [1] , Hsin-I Chiang [1], Neng-Wen Lo [2], Yang-Kwang Fan [1,*] and Jyh-Cherng Ju [1,3,4,5,*]

[1] Department of Animal Science, National Chung Hsing University, Taichung 40227, Taiwan; eve.lumsangkul@gmail.com (C.L.); samchiang@nchu.edu.tw (H.-I.C.)

[2] Department of Animal Science and Biotechnology, Tunghai University, Taichung 40704, Taiwan; nlo@thu.edu.tw

[3] Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan

[4] Translational Medicine Research Center, China Medical University Hospital, Taichung 40402, Taiwan

[5] Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan

* Correspondence: ykfan7712@gmail.com (Y.-K.F.); jcju@dragon.nchu.edu.tw (J.-C.J.); Tel.: +886-4-22052121 (ext. 7601) (J.-C.J.)

Abstract: A teratogenic agent or teratogen can disturb the development of an embryo or a fetus. *Fumonisin* B$_1$ (FB$_1$), produced by *Fusarium verticillioides* and *F. proliferatum*, is among the most commonly seen mycotoxins and contaminants from stale maize and other farm products. It may cause physical or functional defects in embryos or fetuses, if the pregnant animal is exposed to mycotoxin FB$_1$. Due to its high similarity in chemical structure with lipid sphinganine (Sa) and sphingosine (So), the primary component of sphingolipids, FB$_1$ plays a role in competitively inhibiting Sa and So, which are key enzymes in de novo ceramide synthase in the sphingolipid biosynthetic pathway. Therefore, it causes growth retardation and developmental abnormalities to the embryos of hamsters, rats, mice, and chickens. Moreover, maternal FB$_1$ toxicity can be passed onto the embryo or fetus, leading to mortality. FB$_1$ also disrupts folate metabolism via the high-affinity folate transporter that can then result in folate insufficiency. The deficiencies are closely linked to incidences of neural tube defects (NTDs) in mice or humans. The purpose of this review is to understand the toxicity and mechanisms of mycotoxin FB$_1$ on the development of embryos or fetuses.

Keywords: *Fumonisin* B$_1$; developmental toxicity; embryogenesis; NTD; teratogen

Key Contribution: This review summarizes the developmental toxicity effect and possible mechanisms of mycotoxin *Fumonisin* B$_1$ in several animal species, along with future perspectives in some related studies.

1. General Features of *Fumonisin* B$_1$

Mycotoxin *Fumonisin*s (FBs) are fungal secondary metabolites produced by *Fusarium verticillioides* and *F. proliferatum*. They are water soluble and contain two propane-1, 2, 3-tricarboxylic acid side chains, esterified to an aminopolyol backbone. Eighteen different related types have been identified and isolated [1,2]. *Fumonisin* B$_1$ (FB$_1$) is clearly the most abundant analogue and the most prevalent mycotoxin contamination found in stale corn [3–9].

FB$_1$ contamination occurs in maize kernels and biosynthesis of FB$_1$ within the environment of the fungus-colonized kernel can be affected by the kernel composition. FB$_1$ production is at least five times higher in de-germed maize kernels than in germ tissue [10]. FB$_1$ biosynthesis varies with the

developmental age of the tissue with the highest level of FB_1 appearing in the later stages of kernel development [11].

More than 50% of FB_1 contamination has been found in spoiled corn and corn-based products, in many parts of the world. A wild range of concentrations of FB_1 from 6 to 155,000 µg/kg was detected in the investigated corn samples [12–19] that exceeded both the U.S. Food and Drug Administration guidelines and the EU maximum limits in de-germed dry-milled corn products (2000 µg/kg of total FB) [4–8]. In South America, all Brazilian corn meal samples were found to contain 1310 to 19,230 µg/kg of FBs [17]. Maize and maize-based foods, such as the cornflakes and corn snacks, have become an integral part of human life, being consumed on a daily basis. It has been shown that total maize production increased from 832.5 to 1099 million metric tons, globally, between 2011 and 2018 [20,21]. Similarly, total corn consumption around the world summarized by USDA increased from 991 to 1131 thousand metric tons, between 2015 and 2018 [22].

According to WHO (2001), the maximum tolerable daily intake of FBs, for humans, is 2 µg/kg-BW (body weight) [23]. The European Commission (2006 and 2007) also established a maximal FB level of 1000 µg/kg in maize and maize-based food for humans, 800 µg/kg in maize-based breakfast cereals and snacks, and 200 µg/kg in maize-based infant food [24,25]. Therefore, children and infants are the main risk groups for FB_1 toxicity. In Brazil, Tanzania, Guatemala, South Africa, and Argentina [26,27], an assessment revealed that human consumption of FB_1 is above the tolerable daily level. Prevalence of esophageal cancer in Africa and Asia is also the highest in areas with high concentrations of FB_1 contamination reported (between 140,480 and 155,000 µg/kg) [18,19]. As corn is also one of the primary components of animal feeds, animals are also among those at a high risk of FB_1 contamination.

It has been reported that FB_1 induces many animal diseases, such as equine leukoencephalomalacia [28], porcine pulmonary edema syndrome [29], hepatic tumor in rats [30], acute and fatal nephrotoxicity and hepatotoxicity in lambs [31]. Various degrees of toxic responses have been observed in chickens, ducklings, and turkey poults (e.g., decreased body weight gain, increased mortality, reduced size of the bursa of *Fabricius*, thymus, and spleen, myocardial degeneration, myocardial hemorrhage, alterations in the hemostatic mechanism and necrosis of hepatocytes) [32–37]. Therefore, mycotoxins not only pose a significant risk to human and animal health, but also impact food security and reduce livestock production. Doubtless, FB_1 has been one of the most hazardous mycotoxins with regard to animal health that is tightly associated with economic losses.

2. Toxicokinetic of FB_1

Mycotoxin FB_1 is difficult to absorb and can be rapidly excreted (urinary and biliary) in most species [38]. In rats, FB_1 can be excreted with feces (80%) and urine (3%), 96 h after intragastric administration of radiolabeled [^{14}C] FB_1. However, low but consistent FB_1 levels can still be detected in the liver, kidneys, and blood [39]. Although the liver and kidneys are two major target organs retaining most of the absorbed toxins, FB_1 is also found in serum and other tissues in pigs, after oral administration [40,41].

Intestinal absorption of FB_1 and its biliary excretion are involved in the potential interactions between FB_1 and cholesterol [42]. Through interactions with cholesterol and bile salts, such as sodium taurocholate, dietary FB_1 could be incorporated into mixed micelles. Transfer of FB_1 to micelles facilitates its intestinal absorption [42]. A few studies have looked at the transfer of FB_1 from intestine to uterus or eggs. Previous studies in mammalian species suggested that FB_1 could cross the placenta when the pregnant mouse was exposed to FB_1, during the early gestation period (embryonic day 7.5–8.5, E7.5–8.5) [43]. In the early gestation stage, the placenta is not yet well-formed, which potentially leaves the embryos vulnerable to teratogenic insults. However, when pregnant rats were exposed to FB_1 at later gestation period (E15), embryo development was not affected by the toxins, suggesting that the fully developed placenta might provide a protective barrier against a mycotoxin attack [44]. Nevertheless, no evidence has shown such FB_1-placenta or FB_1-egg transportation in humans and in avian species.

The FB_1 molecule includes a long chain aminopentol backbone (AP_1) with two ester-linked tricarballylic acids (TCA), in which AP_1 originates from the hydrolysis of the tricarballylic acid side chains, at carbons 14 and 15; it is then replaced by the hydroxyl groups [45]. Recent studies have demonstrated that swine cecal microbiota can metabolize FB_1 to partially hydrolysed FB_1 ($PHFB_1$) and a small amount of AP_1 [46]. In weaning piglets, the presence of PHB_1 and AP_1 is found in tissues with mostly unmetabolized FB_1 [47].

Based on the intraperitoneal or intravenous dosing, the kinetics of FB_1 elimination is consistent with the one or two-compartment model. Depending on animal species, the initial elimination of FB_1 is rapid with a half-life of approximately 10 to 116 min, among different animals [48–53]. In weaning piglets, however, FB_1, PHB_1, and AP_1 were detected in animal tissues, during a ten-day long elimination period [47].

3. Mechanisms through Which the FB_1 Exerts Its Developmental Toxicity

Teratogens are known to interfere with embryonic or fetal development and cause congenital malformations (birth defects). Potential teratogens include radiation, maternal infections, chemicals and drugs, etc. [54]. In the case of corn contaminated with FB_1, physical or functional defects in human and animal embryos or fetuses are possible when pregnant mothers are exposed. Therefore, FB_1 has also been proven to be among those potential teratogens during embryonic development.

The best-known mechanism of action for FB_1 is closely associated with sphingolipid metabolisms. Due to the similarity of its chemical structure (Figure 1) with Sphinganine (Sa) and sphingosine (So) [1–3,55], FB_1 can interfere with the metabolism of Sa and So, the primary components of sphingolipids. Sphingolipids are widely distributed compounds and are often part of biomembranes. They regulate critical cell functions, such as cell proliferation, differentiation, and apoptosis [56,57]. Therefore, during exposure, FB_1 serves as a competitive inhibitor for the Sa and So key enzymes in the de novo synthesis of ceramide, complicating the sphingolipid biosynthesis pathway (Figure 2) [58–60]. Inhibition of the ceramide synthase leads to a rapid increase of sphinganine, reduced sphingosine, elevated Sa/So, accumulations of the 1-phosphate metabolites of Sa/So, as well as the decreased downstream sphingolipids [61–63].

Figure 1. Comparison of chemical structure of FB_1 and primary components of sphingolipids, sphinganine (Sa) and sphingosine (So). The chemical structure of FB_1 has a high similarity to Sa and So, which all possess an amine group (red circle) attached to the long fatty-acid chain. FB_1 also differs from Sa or So, by the absence of a hydroxymethyl group (blue circle) attached to the head group [1–3,55].

Disturbance in the sphingolipid metabolism is thought to be a major contributor to FB_1 toxicity; it can also interfere with folate transporters. In other words, another developmental toxicity of FB_1 is disruption of folate processing, due to its high-affinity for the folate transporter. This, in turn, can lead to an insufficient transfer of folates to a developing fetus, causing folate-deficient syndromes, during embryogenesis. This phenomenon is similar to that observed when pregnant animals are fed specific vitamin-deficient diets, such as folate-deficient diets. Therefore, FB_1 inhibition of ceramide

biosynthesis can be plausibly linked to folate insufficiency and is closely associated with an increased risk of neural tube defects (NTDs) [64–69].

A possible etiological factor for embryo deaths and fetal malformations is maternal toxicity [70–72]. Collins et al. suggested that FB_1 was not teratogenic but that developmental variations induced by the mycotoxin were secondary to maternal toxicity. Overall, FB_1 exerts secondary to maternal toxicity, which includes growth impairment at high doses and fetal death in utero. In this study, signs of maternal toxicity (increased Sa/So ratios characteristic in maternal livers, kidneys, serum, and brains) were observed in kidneys and livers in all FB_1-treated groups, but with no effect in fetuses [73]. Similarly, Reddy et al. found FB_1-treated mice had increased Sa/So ratios in maternal organs, but not in fetal livers [74]. Therefore, the effects of FB_1 on fetuses, should be considered as secondary to maternal toxicity.

Figure 2. Inhibition of the ceramide synthesis pathway by FB_1. In normal physiology, the amino group of Sphinganine (Sa) and Sphingosine (So) can form an amide bond with fatty acid carboxyl to produce a ceramide. Mycotoxin FB_1 can bind to the catalytic site of ceramide synthase, resulting in an inhibition of the reduction of Sa with fatty acyl CoA forming dihydroceramide. Furthermore, re-acylation of So, derived from breaking down sphingolipids to form ceramide, is also inhibited by FB_1 (red line) [56,59–63,75].

4. *Fumonisin* B_1 and Developmental Toxicity in Animals

As mentioned previously, mycotoxin FB_1 might act as an embryonic or fetal cytotoxic agent (secondary to maternal toxicity), which results in growth retardation and developmental abnormalities, and indirectly induces NTDs when administered to pregnant animals. Previous studies about FB_1 on developmental toxicity in rats, Syrian hamsters, mice, rabbits, humans, ruminants, and chickens are reviewed and summarized in Table 1.

Table 1. The developmental toxicity of mycotoxin *Fumonisin* B_1 in animals and humans.

Species	FB_1 Treatment and Doses	Developmental Toxicity	Reference
Rat (Sprague-Dawley)	Rat embryos cultured in 0.2 to 40.4 ppm FB_1 for 45 h at embryonic day (E) 9.5	Retarded development; increased abnormal embryos phenotype	[44]
Rat (Sprague-Dawley)	Rat embryos cultured in 0, 2.17, 7.22, 21.7, 72.2 or 217 ppm hydrolized FB_1 (HFB$_1$) for 45 h at E9.5	Increased percentage of NTDs and other abnormalities	[76]
Rat (Sprague-Dawley)	Male and female rats fed 0, 1, 10, or 55 ppm FB_1 9 or 2 wk prior to mating	No effect on the peformance of dam or embryos; maternal toxicity by altering sphingolipid metabolism in the livers of dam at the highest dose	[77]
Syrian Hamster	Female hamsters fed 0, 6, 12, 18 mg/kg-BW by gavage on E8–E9	Increased fetal death; malformation at the highest dose	[78]

Table 1. *Cont.*

Species	FB$_1$ Treatment and Doses	Developmental Toxicity	Reference
Syrian Hamster	Pregnant Syrian hamsters given 0, 8.7, 10.4, 12.5, 15, or 18 mg/kg-BW by gavage on E8–E12.	Reduced litter size; decreased fetal weight; reduced body length	[79]
Mouse (ICR)	Mouse embryos cultured with 0, 0.72, 1.44, 2.16, 3.60, 5.05, 10.8, 18.0, 36.0 or 72.1 ppm for 26 h and 36 ppm for 2 h	Induced facial NTDs; growth retardation	[80]
Mouse (LM/Bc)	Pregnant mice injected with 0, 5, 10, 15 and 20 mg/kg-BW/day via intraperitoneal on E7.5 and E8.5	Increased exencephaly from 5% to 79%	[44]
Mouse (LM/Bc)	Female mice treated with 0, 2.5 or 10 mg/kg by intraperitoneal on E7 and E8	NTDs (36%) in 10 mg/kg treated group	[64]
Mouse (CD1)	Female mice fed 0, 12.5, 25, 50 and 100 mg FB$_1$/kg-BW by gavage from E7–E15	Fetal toxicity; increased fetal death; decreased fetal weight	[74]
Mouse (CD1)	Pregnant mice injected with 15, 30 or 45 mg FB$_1$/kg-BW/day (1st trial); 10, 23, 45 or 100 mg/kg-BW/day (2nd trial) via intraperitoneal at E7 and E8	Fetotoxicity; increased NTDs (8–55%)	[81]
Mouse (CD1)	Pregnant mice fed 12.5 mg/kg FB$_1$ at E7.5 and E8.5	NTDs (7.4% exencephaly)	[82]
Mouse (LM/Bc, CD1)	Female mice fed 0, 50 or 150 mg/kg diet at wk 5 before mating and after mating until E16	10% of exencephaly in LM/Bc mice (at 150 mg/kg); No NTDs but fetal death in CD1 mice	[83]
Rabbits (New Zealand White)	Rabbits fed 0, 0.1, 0.5, and 1.0 mg/kg-BW by gavage during E3–E19	Decreased body and organ weights of fetuses	[84]
Rabbits (NewZealand White x Chinchilla)	Male rabbits fed 0.13, 5.0, 7.5 and 10 mg/kg for 28 wk then mated with female rabbits	Induced embryo mortality	[85]
Human neural epithelial cells	Cells treated with 0.00072, 0.0072, 0.072, 0.72, 7.2, and 72 ppm FB$_1$ for 48 h	Altered balance of Sphingosine 1-phosphate	[86]
Bovine oocytes	Cumulus-oocyte complexes matured in 3.6, 7.2, 14.4, 21.6, or 36.0 ppm FB$_1$-containing medium for 22 h	Decreased percentages and quality of matured oocytes and embryos	[87]
Chicken (Columbia x New Hampshire)	Eggs inoculated with 0.72, 7.2 or 72 ppm of FB$_1$ or 14.4 ppm FB$_1$ + 2.82 ppm FB$_2$, and 0.84 ppm moniliformin at the air sac on day 1 or day 10 of incubation	Increased mortality rates; altered brain, beak, and neck development; pathologic changes in livers, kidneys, heart, lungs, musculoskeletal system, intestines, testes, and brains	[88]
Chicken embryos (White Leghorn)	Chicken embryos injected with 0, 0.017, 0.085, 0.17, 0.425, 0.85, 1.275 and 1.74 ppm FB$_1$ at day 1 of incubation	Increased embryonic death	[89]
Chicken embryos (Peterson-Arbor Acres)	Chicken embryos injected with 0 or 0.25 ppm FB$_1$ at 72 h of incubation	Increased embryonic mortality on d 18	[90]

4.1. Mammalian Models

4.1.1. Rats

In vitro studies have shown that FB$_1$ retarded the growth of cultured rat embryos exposed to FB$_1$ concentrations ≥0.2 ppm, for 45 h, starting from E9.5. Phenotypic abnormalities significantly increased when FB$_1$ concentrations were greater than 0.5 ppm and reached 100% prevalence at 1.01–40.4 ppm [44]. Similarly, in rat embryos cultured with aminopentol (AP$_1$; 0, 2.17, 7.22, 21.7, 72.2, or 217 ppm), the hydrolysis product of FB$_1$, a significant increase was observed in the incidence of abnormal embryos (NTDs and other abnormalities) [76]. In both studies, the observed abnormalities were mainly in conjunction with the retardation of overall growth and development, suggesting that both AP$_1$ and FB$_1$ uniformly exert embryo-toxicity, in detriment to the entire embryo.

In contrast, results from an in vivo study found no overt adverse effects on the reproductive performance of either male or female rats, or their offspring when the rats were fed with FB$_1$ (1, 10, or

55 ppm), starting 9 and 2 weeks before mating. Briefly, litter weight gains in the 10 and 55 ppm FB$_1$ groups were slightly decreased; however, gross litter weight and physical development of offspring were not affected. Furthermore, altered sphingolipid ratios, specifically increased sphinganine to sphingosine ratios, were found in the livers of dams from the highest (55 ppm) FB$_1$ treatment group. However, sphingolipid ratios of abdominal sections, containing livers and kidneys, of fetuses showed no differences between the control and the highest dose litters [77].

4.1.2. Hamsters

In Syrian hamsters, fetal body weight and crown-rump length appeared to decrease with the increased fetal deaths observed in dams, when the hamsters were given an oral administration of 6, 12, or 18 mg/kg-BW of FB$_1$ on E8 and E9, respectively [78]. A similar result was also reported in pregnant Syrian hamsters that were given 0, 8.7, 10.4, 12.5, 15, or 18 mg/kg-BW of FB$_1$ by gavage, on E8 through E12. Their litter sizes were significantly reduced when fed with higher doses of FB$_1$ at 15 or 18 mg/kg-BW [79].

4.1.3. Mice

Cultured mouse E9 embryos were exposed to a long-term (0, 0.72, 1.44, 2.16, 3.60, 5.05, 10.8, 18.0, 36.0, or 72.1 ppm FB$_1$, for 26 h) or a short-term (36 ppm FB$_1$ for 2 h) FB$_1$ treatment. For 26 h of exposure, FB$_1$ caused growth retardation and malformations of embryos, at all concentrations equal to or greater than 1.44 ppm. For instance, one of the NTD phenotypes (exencephaly) was observed at concentrations ≥1.44 ppm of FB$_1$ treatments, and its incidence increased from 10% at 1.44 ppm to 48% at 72.1 ppm (the highest concentration). At a 2 h exposure with 36 ppm FB$_1$, the mouse embryo showed a retarded growth, with NTDs and facial hypoplasia observed in 67% and 83% of the tested embryos, respectively, [80].

When inbred LM/Bc mice were given intraperitoneal dosages of FB$_1$ (0, 5, 10, 15, or 20 mg/kg) on E7.5 and E8.5, the incidence of fetuses showing exencephaly increased from 5% at 5 mg/kg to 79% at 20 mg/kg-BW of FB$_1$ treatments [43]. Similarly, Voss et al. found the incidence of NTD litters was 4/11 (36%), at 10 mg/kg-BW (maternal) of the mycotoxin given (intraperitoneal injection) to LM/Bc mice on E7 and E8 [64].

Other experiments have indicated that CD1 mice are more resistant to NTDs induced by FB$_1$ than the LM/Bc mice. Tests on CD1 mice have shown that the fetal toxicity (fetal death and decreased fetal weight) was evident after exposure to FB$_1$ [74]. Voss et al. reported that developmental NTDs were less than 10% when mice were given 10 mg/kg-BW of FB$_1$ [81]; however, FB$_1$ was found to be fetotoxic, at a maternal dose ≥45 mg/kg-BW, where 36% of mouse fetuses with NTDs were induced. Moreover, Liao et al. also showed that CD1 mice fed with 12.5 mg/kg had NTDs in 7.4% of the mouse fetuses examined [82].

The comparison between the LM/Bc and CD1 females by Voss et al. [83] revealed a 10% incidence (1/10 fetuses) of exencephaly in the LM/Bc mouse fetuses, when female mice were fed with diets contaminated with 150 ppm FB$_1$; but no NTDs were found in the CD1 offspring, although the CD1 litters exhibited a higher fetal mortality. Conceivably, differential responses or sensitivity to FB$_1$ treatment could also exist even between these two mouse strains and not only among different animal species.

4.1.4. Rabbits

When given to New Zealand White rabbits by gavage (0, 0.1, 0.5, or 1.0 mg/kg-BW on E3 through E19 embryos), FB$_1$ caused maternal mortality and disrupted maternal sphingolipid metabolism at concentrations ≥0.5 mg/kg-BW. Apparently, FB$_1$ is fetotoxic at the two highest doses of 0.5 and 1.0 mg/kg-BW, as indicated by the reduced fetal body, kidney, and liver weights [84]. Exposure of male rabbits to FB$_1$ contaminated diets with up to 7.5 mg/kg FB$_1$, depressed the testicular and epididymal sperm reserves, the sperm production, and potentially impaired reproduction of the buck, and in

turn, induced embryo mortality, during later development [85]. Evidence of disrupted sphingolipid metabolism was not found in rabbit fetuses, suggesting that the effect of FB_1 on rabbits were also secondary to maternal toxicity.

4.1.5. Humans

Although FB_1 has been identified with significant health threats in livestock and many other animals, evidence for the same in humans is currently inconclusive. Some studies expressed concerns that exposure to FB_1 might contribute to serious adverse health outcomes, such as cancers and birth defects. One study on the incidence of NTDs among Mexican Americans at the Texas–Mexico border, suggested that FB_1 exposure in pregnant women might be a contributing factor to NTDs in babies. The NTD risk can increase in women consuming homemade tortillas, which contain approximately 0.234 ppm FB_1, with daily exposure, approximately 0.1726 mg/day/kg-BW compared to the control group [91]. Callihan et al. suggested that the mechanism of FB_1 action has been confirmed in humans [86]. The alteration of sphingosine 1-phosphate (S1P) and its receptors, during the development of the nervous system, were observed. For instance, human neuroepithelial cells (hES-NEP) treated with various concentrations of (0.00072, 0.0072, 0.072, 0.72, 7.2, or 72 ppm) FB_1, for 48 h, caused the inhibition of ceramide synthases and resulted in an accumulation of sphingoid-based dihydrosphingosine and the bioactive lysophosphosphingolipid dihydro-sphingosine 1-phosphate (dhS1P).

4.1.6. Cattle

The study of FB_1 on developmental toxicity in ruminants is relatively limited, compared to those in other animal species and humans. However, in vitro oocyte maturation (IVM) was compromised by FB_1 treatments, when bovine cumulus-oocyte complexes (COCs) were matured for 22 h, in a maturation medium containing 3.6, 7.2, 14.4, 21.6, or 36.0 ppm of FB_1. Oocytes matured in the medium with 7.2 ppm FB_1, decreased the proportion of the two- to four-celled embryos; oocytes matured with 14.4 ppm FB_1 had no changes in their cleavage rates but showed a reduced blastocyst rate on day 8, post-fertilization. When the highest concentration (36.0 ppm) of FB_1 was used, the most prominent effect on oocyte development was observed, in which the oocytes could not be normally fertilized or developed to the blastocyst stage [87]. In general, bovine oocytes matured in FB_1-containing medium, also compromised the quality of developing embryos.

4.2. Avian Species

Javed et al. inoculated chicken eggs with (0, 0.72, 7.2, or 72 ppm) FB_1 or *Fusarium proliferatum* culture material extract (CME), to provide 14.4 ppm of FB_1 and 2.82 ppm FB_2, on day 1 or day 10 of the 21-day incubation period. They found FB_1 increased embryo mortality from 50% to 100%, when inoculated with FB_1, compared to a 100% mortality in the CME treatment. Early fetal abnormalities including hydrocephalus, enlarged beaks and elongated necks, were also observed in FB_1-exposed embryos; pathologic changes were evident in livers, kidneys, heart, lungs, musculoskeletal system, intestines, testes, and brains, in these toxin-exposed embryos [88]. In agreement with Bacon et al., a significantly increased mortality of embryos was observed in the FB_1-administered group [89]. Another study was performed by Henry et al. to confirm FB_1 toxicity, where broiler embryos were injected with 0 to 0.25 ppm FB_1, followed by 72 h of incubation. By day 18, after FB_1 injection, the cumulative embryonic mortality (56%) drastically increased, compared to the control group (4%) [90]. It is, hence, clearly demonstrated that exposure to mycotoxin FB_1 adversely affected embryo survival and development in poultry. Unlike mammalian species, however, it remains unclear whether maternal exposure to mycotoxin FB_1 (acute and chronic) can cause accumulative effects that could directly carry over to the developing chick embryos. It would be of great interest to develop more in-depth studies to reveal this maternal–fetal portal of *Fumonisin* toxicity.

5. Concluding Remark

Mycotoxin FB$_1$ apparently acts directly or indirectly as an embryotoxic or fetotoxic teratogen to cause growth retardation, delayed or incomplete organogenesis, malformations, and ultimately fetal death, in several species, largely in a dose-dependent manner. Based on histopathological and sphingolipid profile assessments of the dams, fetotoxicity secondary to maternal toxic effects are also prominent. The mechanism of action for the toxicity of mycotoxin FB$_1$ is understood to be through the competitive inhibitors of ceramide synthase in the de novo sphingolipid biosynthetic pathway. However, there is still no adequate evidence to implicate the initial alterations caused by FB$_1$, particularly during early embryogenesis; similar studies in domestic species are also largely unavailable. Nevertheless, comparative studies between sensitive and non-sensitive animals might be necessary to determine which animal model is most relevant to humans. It would be useful to further investigate the specific toxicity and derive more conclusive mechanisms in *Homo sapiens.* Furthermore, due to the frequent higher level of FB$_1$ contaminants, compared to the safety allowance recommended by the European Union (Commission of European Communities) and the USFDA Center for Food Safety and Nutrition, it is essential to develop an effective strategy to minimize risks of FB$_1$ exposure for both animal species and human beings.

References

1. Branham, B.E.; Plattner, R.D. Isolation and characterization of a new *Fumonisin* from liquid cultures of *Fusarium moniliforme*. *J. Nat. Prod.* **1993**, *56*, 1630–1633. [CrossRef]

2. Cawood, M.E.; Gelderblom, W.C.A.; Vleggaar, R.; Behrend, Y.; Thiel, P.G.; Marasas, W.F.O. Isolation of the *Fumonisin* mycotoxins—A quantitative approach. *J. Agric. Food Chem.* **1991**, *39*, 1958–1962. [CrossRef]

3. Voss, K.A.; Smith, G.W.; Haschek, W.M. *Fumonisin*s: Toxicokinetics, mechanism of action and toxicity. *Anim. Feed Sci. Technol.* **2007**, *137*, 299–325. [CrossRef]

4. Voss, K.A.; Riley, R.T. *Fumonisin* toxicity and mechanism of action: Overview and current perspectives. *Food Saf.* **2013**, *1*, 49–69. [CrossRef]

5. Smith, G.W. *Fumonisin*s. In *Veterinary Toxicology*, 3rd ed.; Gupta, R., Ed.; Elsevier: New York, NY, USA, 2018; pp. 1003–1018.

6. Murphy, P.A.; Rice, L.G.; Ross, P.F. *Fumonisin* B$_1$, B$_2$ and B$_3$ content of Iowa, Wisconsin and Illinois cornand corn screenings. *J. Agric. Food Chem.* **1993**, *41*, 263–266. [CrossRef]

7. Thiel, P.G.; Marasas, W.F.O.; Sydenham, E.W.; Shephard, G.S.; Gelderblom, W.C.A.; Nieuwenhuis, J.J. Survey of *Fumonisin* production by *Fusarium* species. *Appl. Environ. Microbiol.* **1991**, *57*, 1089–1093. [PubMed]

8. Chandrasekhar, S.; Sreelakshmi, L. Formal synthesis of *Fumonisin* B$_1$, a potent sphingolipid biosynthesis inhibitor. *Tetrahedron Lett.* **2012**, *53*, 3233–3236. [CrossRef]

9. ApSimon, J.W. Structure, synthesis, and biosynthesis of *Fumonisin* B$_1$ and related compounds. *Environ. Health Perspect.* **2001**, *109*, 245–249. [CrossRef]

10. Shim, W.B.; Flaherty, J.E.; Woloshuk, C.P. Comparison of *Fumonisin* B$_1$ biosynthesis in maize germ and degermed kernels by *Fusarium verticillioides*. *J. Food Prot.* **2003**, *66*, 2116–2122. [CrossRef]

11. Warfield, C.Y.; Gilchrist, D.G. Influence of kernel age on *Fumonisin* B$_1$ production in maize by *Fusarium moniliforme*. *Appl. Environ. Microbiol.* **1999**, *65*, 2853–2856.

12. Liu, Y.X.; Jiang, Y.; Li, R.J.; Pang, M.H.; Liu, Y.C.; Dong, J.G. Natural occurrence of *Fumonisin*s B$_1$ and B$_2$ in maize from eight provinces of China in 2014. *Food Addit. Contam. B* **2017**, *10*, 113–117. [CrossRef] [PubMed]

13. Pinotti, L.; Ottoboni, M.; Giromini, C.; Dell'Orto, V.; Cheli, F. Mycotoxin Contamination in the EU Feed Supply Chain: A Focus on Cereal Byproducts. *Toxins* **2016**, *8*, 45. [CrossRef] [PubMed]

14. Tseng, C.T.; Liu, T.Y. Occurrence of *Fumonisin* B_1 in maize imported into Taiwan. *Int. J. Food Microbiol.* **2001**, *65*, 23–26. [CrossRef]

15. Tseng, C.T.; Liu, T.Y. Occurrence of *Fumonisin* B_1 and B_2 in corn-based foodstuffs in Taiwan market. *Mycopathologia* **1997**, *137*, 57–61. [CrossRef] [PubMed]

16. Tseng, C.T.; Liu, T.Y. Natural Occurrence of *Fumonisin*s B_1 and B_2 in Domestic Maize of Taiwan. *Agric. Food Chem.* **1999**, *47*, 4799–4801. [CrossRef]

17. Bittencourt, A.B.F.; Oliveira, C.A.F.; Dilkin, P.; Correa, B. Mycotoxin occurrence in corn meal and flour traded in Sao Paulo, Brazil. *Food Control* **2005**, *16*, 117–120. [CrossRef]

18. Chu, F.S.; Li, G.Y. Simultaneous occurrence of *Fumonisin* B_1 and other mycotoxins in moldy corn collected from the People's Republic of China in regions with high incidences of esophageal cancer. *Appl. Environ. Microbiol.* **1994**, *60*, 847–852. [PubMed]

19. Rheeder, J.; Marasas, W.; Theil, P.; Sydenham, E.; Shephard, G.; Van Schalkwyk, D. *Fusarium moniliforme* and *Fumonisin*s in corn in relation to human esophageal cancer in Transkei. *Phytopathology* **1992**, *82*, 353–357. [CrossRef]

20. World Agricultural Production Foreign Agricultural Service Circular WAP 3–13 March 2013. Available online: http://www.fas.usda.gov/data/world-agricultural-production (accessed on 13 March 2013).

21. World Agricultural Production Foreign Agricultural Service Circular WAP 12–18 December 2018. Available online: http://www.fas.usda.gov/data/world-agricultural-production (accessed on 18 December 2018).

22. World Agricultural Production Foreign Agricultural Service Circular. Grain: World Markets and Trade December 2018. Available online: http://www.fas.usda.gov/data/grain-world-markets-and-trade (accessed on 18 December 2018).

23. World Health Organization (WHO). *Fumonisins* . In *Safety Evaluation of Certain Mycotoxins in Food*; WHO Food Additives Series 47; FAO Food and Nutrition Paper 74; WHO: Geneva, Switzerland, 2001.

24. European Commission (EC). Regulation (EC) No. 1881/2006 of 19/12/2006. *Off. J. Eur. Union* **2006**, *L364*, 5–24.

25. European Commission (EC). Regulation (EC) No. 1126/2007 of 28/9/2007. *Off. J. Eur. Union* **2007**, *L255*, 14–17.

26. Martin, S.; Ramos, A.J.; Cano-Sancho, G.; Sanchis, V. Mycotoxins: Occurrence, toxicology, and exposure assessment. *Food Chem. Toxicol.* **2013**, *60*, 218–237. [CrossRef] [PubMed]

27. Scientific Committee on Food (SCF). *Updated Opinion of the Scientific Committee on Food on Fumonisin B_1, B_2 and B_3*; Scientific Committee on Food SCF/CS/CNTM/MYC/28 Final; Directorate—Scientific Opinions; European Commission: Brussels, Belgium, 2003.

28. Marasas, W.F.O.; Kellerman, T.S.; Pienaar, J.G.; Naude, T.W. Leukoencephalomalacia: A mycotoxicosis of Equidae caused by *Fusarium moniliforme* Sheldon. *Onderstepoort J. Vet. Res.* **1976**, *43*, 113–122. [PubMed]

29. Kriek, N.P.J.; Kellerman, T.S.; Marasas, W.F.O. A comparative study of the toxicity of *Fusarium verticilliodes (F. moniliforme)* to horses, primates, pigs, sheep and rats. *Onderstepoort J. Vet. Res.* **1981**, *4*, 129–131.

30. Gelderblom, W.C.A.; Snyman, S.D. Mutagenicity of potentially carcinogenic mycotoxins produced by *Fusarium moniliforme*. *Mycotoxin Res.* **1991**, *7*, 46–52. [CrossRef] [PubMed]

31. Edrington, T.S.; Kamps-Holtzapple, C.A.; Harvey, R.B.; Kubena, L.F.; Elissalde, M.H.; Rottinghaus, G.E. Acute hepatic and renal toxicity in lambs dosed with *Fumonisin*-containing culture material. *J. Anim. Sci.* **1995**, *73*, 508–515. [CrossRef] [PubMed]

32. Jeschke, N.; Nelson, P.E.; Marasas, W.F.O. Toxicity to ducklings of *Fusarium moniliforme* isolated from corn intended for use in poultry feed. *Poult. Sci.* **1987**, *66*, 1619–1623. [CrossRef]

33. Engelhardt, J.A.; Carlton, W.W.; Tuite, J.F. Toxicity of *Fusarium moniliforme* var. *subglutinans* for chicks, ducklings and turkey poults. *Avian Dis.* **1989**, *33*, 357–360.

34. Marijanovic, D.R.; Holt, P.; Norred, W.P.; Bacon, C.W.; Voss, K.A.; Stancel, P.C. Immunosuppressive effects of *Fusarium moniliforme* corn cultures in chicken. *Poult. Sci.* **1991**, *70*, 1895–1901. [CrossRef]

35. Javed, T.; Bennett, G.A.; Richard, J.L.; Dombrink-Kurtzman, M.A.; Cote, L.M.; Buck, W.B. Mortality in broiler chicks on feed amended with *Fusarium proliferatum* culture material or with purified *Fumonisin* B_1 and *moniliforme*. *Mycopathologia* **1993**, *123*, 171–184. [CrossRef]

36.   Espada, Y.; Gopegui, R.R.; Cuadradas, C.; Cabanes, F.J. *Fumonisin* mycotoxicoses in broilers: Plasma protein and coagulation modifications. *Avian Dis.* **1997**, *41*, 73–79. [CrossRef]

37.   Weibking, T.S.; Ledoux, D.R.; Brown, T.P.; Rottinghaus, G.E. *Fumonisin* toxicity in turkeys. *J. Vet. Diagn. Investig.* **1993**, *5*, 75–83. [CrossRef] [PubMed]

38.   Joint Expert Committee on Food Additives 47 (JECFA). *Fumonisins, 47th Report of the Joint Expert Committee on Food Additives*; World Health Organization: Geneva, Switzerland, 2001.

39.   Norred, W.P.; Plattner, R.D.; Chamberlain, W.J. Distribution and excretion of [14]C *Fumonisin* B_1 in male sprague-dawley rats. *Nat. Toxins* **1993**, *1*, 341–346. [CrossRef] [PubMed]

40.   Meyer, K.; Mohr, K.; Bauer, J.; Horn, P.; Kovács, M. Residue formation of *Fumonisin* B_1 in porcine tissues. *Food Addit. Contam.* **2003**, *20*, 639–647. [CrossRef] [PubMed]

41.   Fodor, J.; Meyer, K.; Riedlberger, M.; Bauer, J.; Horn, P.; Kovacs, F.; Kovacs, M. Distribution and elimination of *Fumonisin* analogues in weaned piglets after oral administration of *Fusarium verticillioides* fungal culture. *Food Addit. Contam.* **2006**, *23*, 492–501. [CrossRef] [PubMed]

42.   Mahfoud, R.; Maresca, M.; Santelli, M.; Pfohl-Leszkowicz, A.; Puigserver, A.; Fantini, J. pH-dependent interaction of *Fumonisin* B_1 with cholesterol: Physicochemical and molecular modeling studies at the air-water interface. *J. Agric. Food Chem.* **2002**, *50*, 327–331. [CrossRef] [PubMed]

43.   Gelineau-van Waes, J.; Starr, L.; Maddox, J.; Aleman, F.; Voss, K.A.; Wilberding, J.; Riley, R.T. Maternal *Fumonisin* exposure and risk for neural tube defects: Mechanisms in an in vivo mouse model. *Birth Defects Res. A Clin. Mol. Teratol.* **2005**, *73*, 487–497. [CrossRef] [PubMed]

44.   Flynn, T.J.; Pritchard, D.; Bradlaw, J.; Eppley, R.; Page, S. In vitro embryo toxicity of *Fumonisin* B_1 evaluated with cultured post implantation staged embryos. *Toxicol. In Vitro* **1996**, *9*, 271–279.

45.   Merrill, A.H.; Wang, E.; Gilchrist, D.G.; Riley, R.T. *Fumonisin*s and other inhibitors of de novo sphingolipid biosynthesis. *Adv. Lipid Res.* **1993**, *26*, 215–234.

46.   Fodor, J.; Meyer, K.; Gottschalk, C.; Mamet, R.; Kametler, L.; Bauer, J.; Horn, P.; Kovacs, F.; Kovacs, M. In vitro microbial metabolism of *Fumonisin* B_1. *Food Addit. Contam.* **2007**, *24*, 416–420. [CrossRef]

47.   Fodor, J.; Balogh, K.; Weber, M.; Miklós, M.; Kametler, L.; Pósa, R.; Mamet, R.; Bauer, J.; Horn, P.; Kovács, F.; et al. Absorption, distribution and elimination of *Fumonisin* B(1) metabolites in weaned piglets. *Food Addit. Contam.* **2008**, *25*, 88–96. [CrossRef]

48.   Shephardm, G.S.; Thiel, P.G.; Sydenham, E.W.; Alberts, J.F.; Gelderblom, W.C. Fate of a single dose of the ^{14}C-labelled mycotoxin, *Fumonisin* B_1, in rats. *Toxicon* **1992**, *30*, 768–770. [CrossRef]

49.   Shephard, G.S.; Thiel, P.G.; Sydenham, E.W.; Savard, M.E. Fate of a single dose of ^{14}C-labelled *Fumonisin* B_1 in vervet monkeys. *Nat. Toxins* **1995**, *3*, 145–150. [CrossRef] [PubMed]

50.   Prelusky, D.B.; Savard, M.E.; Trenholm, H.L. Pilot study on the plasma pharmacokinetics of *Fumonisin* B_1 in cows following a single dose by oral gavage or intravenous administration. *Nat. Toxins* **1995**, *3*, 389–394. [CrossRef] [PubMed]

51.   Vudathala, D.K.; Prelusky, D.B.; Ayroud, M.; Trenholm, H.L.; Miller, J.D. Pharmacokinetic fate and pathological effects of [14]C *Fumonisin* B_1 in laying hens. *Nat. Toxins* **1994**, *2*, 81–88. [CrossRef] [PubMed]

52.   Prelusky, D.B.; Miller, J.D.; Trenholm, H.L. Disposition of ^{14}C-derived residues in tissues of pigs fed radiolabelled *Fumonisin* B_1. *Food Addit. Contam.* **1996**, *13*, 155–162. [CrossRef] [PubMed]

53.   Tardieu, D.; Bailly, J.D.; Skiba, F.; Grosjean, F.; Guerre, P. Toxicokinetics of *Fumonisin* B_1 in turkey poults and tissue persistence after exposure to a diet containing the maximum European tolerance for *Fumonisin*s in avian feeds. *Food Chem. Toxicol.* **2008**, *46*, 3213–3218. [CrossRef] [PubMed]

54.   Faqi, A.S.; Hoberman, A.; Lewis, E.; Stump, D. Developmental and Reproductive Toxicology. In *A Comprehensive Guide to Toxicology in Preclinical Drug Development*; Faqi, A.S., Ed.; Elsevier: New York, NY, USA, 2013; pp. 335–364.

55.   Braun, M.S.; Wink, M. Exposure, occurrence, and chemistry of *Fumonisin*s and their cryptic derivatives. *Compr. Rev. Food Sci. Food Saf.* **2018**, *2018*, 769–791. [CrossRef]

56.   Rao, R.P.; Vaidyanathan, N.; Rengasamy, M.; Oommen, A.M.; Somaiya, N.; Jagannath, M.R. Sphingolipid Metabolic Pathway: An Overview of Major Roles Played in Human Diseases. *J. Lipids* **2013**, *2013*, 1–12.

57.   Chen, Y.; Liu, Y.; Sullards, M.C.; Merrill, A.H. An introduction to sphingolipid metabolism and analysis by new technologies. *NeuroMol. Med.* **2010**, *12*, 306–319. [CrossRef]

58.   Stockmann-Juvala, H.; Savolainen, K. A review of the toxic effects and mechanisms of action of *Fumonisin* B_1. *Hum. Exp. Toxicol.* **2008**, *27*, 799–809. [CrossRef]

59. Voss, K.A.; Riley, R.T.; Gelineau-Van Waes, J. *Fumonisin*s. In *Reproductive and Developmental Toxicology*, 1st ed.; Gupta, R., Ed.; Elsevier: New York, NY, USA, 2011; pp. 725–737.

60. Voss, K.A.; Riley, R.T.; Gardner, N.M.; Gelineau-Van Waes, J. *Fumonisin*s. In *Reproductive and Developmental Toxicology*, 2nd ed.; Gupta, R., Ed.; Elsevier: New York, NY, USA, 2017; pp. 925–943.

61. Wang, E.; Norred, W.P.; Bacon, C.W.; Riley, R.T.; Merril, A.H. Inhibition of Sphingolipid Biosynthesis by *Fumonisin*s. *J. Biol. Chem.* **1991**, *266*, 14486–14490. [PubMed]

62. Voss, K.A.; Riley, R.T.; Snook, M.E.; Gelineau-van Waes, J. Reproductive and sphingolipid metabolic effects of *Fumonisin* B$_1$ and its alkaline hydrolysis product in LM/Bc mice: Hydrolyzed *Fumonisin* B$_1$ did not cause neural tube defects. *Toxicol. Sci.* **2009**, *112*, 459–467. [CrossRef]

63. Merrill, A.H., Jr.; Sullards, M.C.; Wang, E.; Voss, K.A.; Riley, R.T. Sphingolipid metabolism: Roles in signal transduction and disruption by *Fumonisin*s. *Environ. Health Perspect.* **2001**, *109*, 283–289. [PubMed]

64. Voss, K.A.; Riley, R.T.; Gelineau-van Waes, J. *Fumonisin* B$_1$ induced neural tube defects were not increased in LM/Bc mice fed folate-deficient diet. *Mol. Nutr. Food Res.* **2014**, *58*, 1190–1198. [CrossRef] [PubMed]

65. Marasas, W.F.O.; Riley, R.T.; Hendricks, K.A.; Stevens, V.L.; Sadler, T.W.; Gelineau-van Waes, J.; Missmer, S.T.; Cabrera, J.; Torres, O.; Gelderblom, W.C.; et al. *Fumonisin*s disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: A potential risk factor for human neural tube defects among populations consuming *Fumonisin*-contaminated maize. *J. Nutr.* **2004**, *134*, 711–716. [CrossRef]

66. Gelineau-van Waes, J.; Voss, K.A.; Stevens, V.L.; Speer, M.C.; Riley, R.T. Maternal *Fumonisin* Exposure as a Risk Factor for Neural Tube Defects. *Adv. Food Nutr. Res.* **2009**, *56*, 145–181.

67. Saitsu, H.; Ishibashi, M.; Nakano, H.; Shiota, K. Spatial and temporal expression of folate-binding protein 1 (Fbp1) is closely associated with anterior neural tube closure in mice. *Dev. Dyn.* **2003**, *226*, 112–117. [CrossRef]

68. Stevens, V.L.; Tang, J. *Fumonisin* B$_1$-induced sphingolipid depletion inhibits vitamin uptake via the glycosylphosphatidylinositol-anchored folate receptor. *J. Biol. Chem.* **1997**, *272*, 18020–18025. [CrossRef]

69. Abdel Nour, A.M.; Ringot, D.; Gueant, J.L.; Chango, A. Folate receptor and human reduced folate carrier expression in HepG2 cell line exposed to *Fumonisin* B$_1$ and folate deficiency. *Carcinogenesis* **2007**, *28*, 2291–2297. [CrossRef]

70. Khera, K.S. Maternal toxicity: A possible etiological factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species. *Teratology* **1985**, *31*, 129–153. [CrossRef]

71. Giavini, E.; Menegola, E. The problem of maternal toxicity in developmental toxicity studies. *Regul. Toxicol. Pharmacol.* **2012**, *62*, 568–570. [CrossRef] [PubMed]

72. Danielsson, B.R. Maternal toxicity. *Methods. Mol. Biol.* **2013**, *947*, 311–325.

73. Collins, T.F.; Sprando, R.L.; Black, T.N. Effects of *Fumonisin* B$_1$ in pregnant rats: Part 2. *Food Chem. Toxicol.* **1998**, *36*, 673–685. [CrossRef]

74. Reddy, R.V.; Johnson, G.; Rottinghaus, G.E.; Casteel, S.W.; Reddy, C.S. Developmental effects of *Fumonisin* B$_1$ in mice. *Mycopathologia* **1996**, *134*, 161–166. [CrossRef] [PubMed]

75. Dragan, Y.P.; Bidlack, W.R.; Cohen, S.M.; Goldsworthy, T.L.; Hard, G.C.; Howard, P.C.; Riley, R.T.; Voss, K.A. Implications of Apoptosis for Toxicity, Carcinogenicity, and Risk Assessment: *Fumonisin* B$_1$ as an Example. *Toxicol. Sci.* **2001**, *61*, 6–17. [CrossRef]

76. Flynn, T.J.; Stack, M.E.; Troy, A.L.; Chirtel, S.J. Assessment of the embryotoxic potential of the total hydrolysis product of *Fumonisin* B$_1$ using cultured organogenesis-staged rat embryos. *Food Chem. Toxicol.* **1997**, *35*, 1135–1141. [CrossRef]

77. Voss, K.A.; Bacon, C.W.; Norred, W.P.; Chapin, R.E.; Chamberlain, W.J.; Plattner, R.D. Meredith FI. Studies on the reproductive effects of *Fusarium moniliforme* culture material in rats and the biodistribution of [^{14}C] *Fumonisin* B$_1$ in pregnant rats. *Nat. Toxins* **1996**, *4*, 24–33. [CrossRef]

78. Floss, J.L.; Casteel, S.W.; Johnson, G.C.; Rottinghaus, G.E.; Krause, G.F. Developmental toxicity of *Fumonisin* in Syrian hamsters. *Mycopathologia* **1994**, *128*, 33–38. [CrossRef]

79. Penner, J.D.; Casteel, S.W.; Pittman, L.; Rottinghaus, G.E.; Wyatt, R.D. Developmental toxicity of purified *Fumonisin* B$_1$ in pregnant Syrian hamsters. *J. Appl. Toxicol.* **1998**, *18*, 197–203. [CrossRef]

80. Sadler, T.W.; Merrill, A.H.; Stevens, V.L.; Sullards, M.C.; Wang, E.; Wang, P. Prevention of *Fumonisin* B$_1$–induced neural tube defects by folic acid. *Teratology* **2002**, *66*, 169–176. [CrossRef]

81. Voss, K.A.; Riley, R.T.; Gelineau-Van Waes, J.B. Fetotoxicity and neural tube defects in CD1 mice exposed to the mycotoxin *Fumonisin* B$_1$. *Mycotoxins* **2007**, *57*, 67–72. [CrossRef]

82. Liao, Y.J.; Yang, J.R.; Chen, S.E.; Wu, S.J.; Huang, S.Y.; Lin, J.J.; Chen, L.R.; Tang, P.C. Inhibition of *Fumonisin* B$_1$ Cytotoxicity by Nanosilicate Platelets during Mouse Embryo Development. *PLoS ONE* **2014**, *9*, e112290. [CrossRef] [PubMed]

83. Voss, K.A.; Gelineau-van Waes, J.B.; Riley, R.T. *Fumonisin*s: Current research trends in developmental toxicology. *Mycotoxin Res.* **2006**, *22*, 61–69. [CrossRef] [PubMed]

84. LaBorde, J.B.; Terry, K.K.; Howard, P.C.; Chen, J.J.; Collins, T.F.X.; Shackelford, M.E.; Hansen, D.K. Lack of embryotoxicity of *Fumonisin* B$_1$ in New Zealand white rabbits. *Fundam. Appl. Toxicol.* **1997**, *40*, 120–128. [CrossRef]

85. Ewuola, E.O.; Egbunike, G.N. Effects of dietary *Fumonisin* B$_1$ on the onset of puberty, semen quality, fertility rates and testicular morphology in male rabbits. *Reproduction* **2010**, *139*, 439–445. [CrossRef]

86. Callihan, P.; Zitomer, N.C.; Stoeling, M.V.; Kennedy, P.C.; Lynch, K.R.; Riley, R.T.; Hooks, S.B. Distinct generation, pharmacology, and distribution of sphingosine 1-phosphate and dihydrosphingosine 1-phosphate in human neural progenitor cells. *Neuropharmacology* **2012**, *62*, 988–996. [CrossRef]

87. Kalo, D.; Roth, Z. Involvement of the sphingolipid ceramide in heat shock induced apoptosis of bovine oocytes. *Reprod. Fertil. Dev.* **2011**, *23*, 876–888. [CrossRef]

88. Javed, T.; Richard, J.L.; Bennett, G.A.; Dombrink-Kurtzman, M.A.; Bunte, R.M.; Koelkebeck, K.W.; Cote, L.M.; Leeper, R.W.; Buck, W.B. Embryopathic and embryocidal effects of purified *Fumonisin* B$_1$ or *Fusarium proliferatum* culture material extract on chicken embryos. *Mycopathologia* **1993**, *123*, 185–193. [CrossRef]

89. Bacon, C.W.; Porter, J.K.; Norred, W.P. Toxic interaction of *Fumonisin* B$_1$ and fusaric acid measured by injection into fertile chicken egg. *Mycopathologia* **1995**, *129*, 29–35. [CrossRef]

90. Henry, M.H.; Wyatt, R.D. The Toxicity of *Fumonisin* B$_1$, B$_2$, and B$_3$, individually and in combination, in chicken embryos. *Poult. Sci.* **2001**, *80*, 401–407. [CrossRef]

91. Missmer, S.A.; Suarez, L.; Felkner, M.; Wang, E.; Merrill, A.H.; Rothman, K.J.; Hendricks, K.A. Exposure to *Fumonisin*s and the occurrence of neural tube defects along the Texas-Mexico border. *Environ. Health Perspect.* **2006**, *114*, 237–241. [CrossRef] [PubMed]